Spotlight on ACC 2026: Dyslipidaemia Guideline Updates and Emerging Data
-
17m 11sPart 1 | Session 2 Emerging Insights on Non-Statin Treatments
-
8m 47sPart 2 Personalised Risk Assessment
-
7m 45s
-
7m 29sPart 4 Lifestyle and Nutrition
-
8m 44sPart 5 Use of Biomarkers
-
5m 28s
Advances in lipid-lowering therapies have expanded the treatment landscape beyond statins, yet a clear gap remains in their routine clinical adoption. Despite strong and growing evidence supporting the use of non-statin agents, many clinicians face challenges integrating these therapies into practice. Bridging this gap requires both a deeper understanding of emerging therapies and practical guidance on how to apply evolving clinical guidelines.
This educational programme is designed to support healthcare professionals in navigating these challenges, providing a focused spotlight on the Dyslipidaemia guideline updates and emerging data presented at ACC 2026. Through a series of expert-led sessions recorded at ACC 2026, participants will gain actionable insights across key areas:
Intensive LDL-C lowering - Dr Steven Nissen (Cleveland Clinic, Cleveland, US) and Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) share strategies to optimise therapy.
Triglyceride management, personalised risk assessment, biomarker integration, and lifestyle interventions – Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, US) and Dr Roger Blumenthal (Johns Hopkins University School of Medicine, Baltimore, US) explore practical approaches to comprehensive cardiovascular care.
Each session is tailored to address real-world clinical challenges, translating evidence into practice and supporting clinicians in delivering more effective, individualised care for patients at cardiovascular risk.
Key Learning Objectives
- Summarise the latest recommendations from the joint ACC/AHA dyslipidaemia guideline on LDL-C and triglyceride lowering, risk assessment, biomarker testing and lifestyle management
- Summarise the latest recommendations from the ACC/AHA on the use of non-statin LDL-C lowering agents in high-risk patients and in that intolerant to statin
- Translate new recommendations with those made on previous European guidelines into your daily practice
- Describe how non-statin treatments achieve their clinical benefit
- Recall MACE benefit of LDL-C lowering agents in patients unable or unwilling to take statins
Target Audience
- Cardiovascular Specialists
- Cardiologists
- Internal Medicine
- Lipidologists
- Endocrinologists
More from this programme
Part 1
Intensive LDL-C Lowering: Life Beyond Statins
Dr Nissen and Dr Ballantyne review recent guideline updates on non-statin therapies, focusing on strategies for statin-intolerant patients and post-ACS management. The session highlights how these novel treatments are being integrated into clinical practice. Emerging data from selected posters provides insights into efficacy, safety, and patient outcomes, offering a concise update on evolving approaches to LDL-C reduction beyond traditional statins.
This session is supported by an unrestricted educational grant from Esperion Therapeutics.
Part 2
Personalised Risk Assessment
Dr Michos and Dr Blumenthal review tools like the PREVENT calculator and SCORE2/SCORE2-OP, highlighting how risk modifiers can refine cardiovascular risk prediction for individual patients.
| 1 session | |
| Personalised Risk Assessment | Watch now |
Part 3
Reframing Triglyceride Management
Dr Michos and Dr Blumenthal explore strategies for reducing cardiovascular risk with EPA, the role of fibrates, and emerging approaches for treating familial chylomicronaemia syndrome, which now includes two approved APOC-III inhibitors.
| 1 session | |
| Reframing Triglyceride Management | Watch now |
Part 4
Lifestyle and Nutrition
Dr Michos and Dr Blumenthal summarise current evidence from recent trials and guidelines, emphasising practical strategies for cardiovascular risk reduction through diet and lifestyle interventions.
| 1 session | |
| Lifestyle and Nutrition | Watch now |
Part 5
Use of Biomarkers
Dr Michos and Dr Blumenthal cover testing recommendations, strategies for risk modification, and emerging therapies targeting key cardiovascular biomarkers.
| 1 session | |
| Use of Biomarkers | Watch now |
Part 6
Top Takeaways from the 2026 Dyslipidaemia Guidelines
Dr Navar summarises key recommendations from the 2026 Dyslipidaemia Guidelines that are shaping the future of lipid management.
Faculty Biographies
Christie Ballantyne
Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention
Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.
He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.
Dr Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions,…
Steven E Nissen
Cardiologist
Dr Steven E. Nissen, an esteemed American cardiologist, researcher, and patient advocate, has left an indelible mark in the field of cardiology. Formerly the chairman of cardiovascular medicine at the renowned Cleveland Clinic in Ohio, Dr Nissen brings a wealth of experience and expertise to his roles.
Joining the Cleveland Clinic in 1992, Dr. Nissen held key positions, including Vice-Chairman of the Department of Cardiology, Section Head of Clinical Cardiology, and Director of the Coronary Intensive Care Unit. In his most recent role, he served as the Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), overseeing multi-center clinical trials. Dr Nissen continues to contribute periodically in the Cardiac Critical Care Unit, showcasing his ongoing commitment to patient care.
A highly accomplished academic, Dr Nissen graduated from the Webb School of California before pursuing his undergraduate degree at the University of Michigan. He earned…
Comments